GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Collaborations
  • Careers
  • Contact
  • Menu Menu

News Archive

GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology

01/10/2019/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology. “We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that […]

Read more

GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting

12/07/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]

Read more

GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe

11/12/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]

Read more

GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

11/09/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. […]

Read more

Genetic Engineering & Biotechnology News: Microfluidic dragnet catches most-wanted antibodies – GigaGen exhaustively interrogates antibodies to find drug candidates

11/02/2018/by jkeller

“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech. “When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central […]

Read more

GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies

10/26/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos […]

Read more

Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth

08/14/2018/by jkeller

The National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped […]

Read more

GigaGen CEO Dave Johnson on Biotech Nation Radio – Ep. 18-31

08/03/2018/by jkeller

Listen to Moira Gunn’s interview with GigaGen CEO Dave Johnson, PhD, on developing next generation I/O drugs to fight cancer on  Biotech Nation Radio

Read more

Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development

06/06/2018/by jkeller

Antibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited […]

Read more

GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology

05/03/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols.  Read the full press release.  

Read more

GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit

04/30/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using […]

Read more

GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018

04/09/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago. Read the full […]

Read more

Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017

04/06/2018/by jkeller

Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine. Read the full story.

Read more

GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs

02/27/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology […]

Read more

GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology

02/26/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology. Read the full press release.

Read more

Biotech Showcase 2018

02/22/2018/by jkeller

David S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy. Watch the video.

Read more

GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences

02/12/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, […]

Read more

Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley

02/08/2018/by jkeller

I think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather […]

Read more

Natively Paired Antibodies Are Better: Study by GigaGen in Collaboration with Global Biopharmaceutical Company Describes Novel Approach to Identifying Antibodies with High Therapeutic Potential

02/05/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing a pipeline of novel antibody therapies, has published a study in collaboration with authors from a leading antibody drug developer that sheds new light on methods for increasing the success of antibody discovery in mice. The study, “A natively paired antibody library yields drug leads with higher sensitivity and […]

Read more

GigaGen Announces New Office Space in South San Francisco

01/23/2018/by jkeller

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that in order to expand operations it has moved to larger office facilities located at One Tower Place, Suite 750, in South San Francisco, CA. GigaGen now occupies the 7th floor of the building, with the roughly 15,000 square foot area affording ample state-of-the-art […]

Read more
Page 3 of 41234

Latest Tweets

GigaGenFollow

GigaGen
GigaGen@gigageninc·
16 Apr

We are advancing an anti- #CTLA4 #antibody with a unique profile that has the potential to provide enhanced efficacy and reduced toxicity against #tumors. Learn more here: https://bit.ly/3tlV5vg

Reply on Twitter 1383042739969867778Retweet on Twitter 1383042739969867778Like on Twitter 13830427399698677781Twitter 1383042739969867778
GigaGen@gigageninc·
15 Apr

Today we published research on our recombinant hyperimmune globulins in @NatureBiotech The data describe our proprietary technology used for the production of a new class of #antibody drugs, including our novel #COVID19 therapy. Read more: https://bit.ly/3ge9XbK

Reply on Twitter 1382729196217196546Retweet on Twitter 13827291962171965462Like on Twitter 13827291962171965467Twitter 1382729196217196546
GigaGen@gigageninc·
23 Mar

Today we announced we’ll be presenting a poster at @AACR Virtual Annual Meeting highlighting data that support the potential of dual PD-L1/TGF- β blockade to overcome resistance to first generation #oncology immunotherapies. Learn more: https://bit.ly/3seKkLp #AACR2021

Reply on Twitter 1374363950926737409Retweet on Twitter 13743639509267374091Like on Twitter 13743639509267374095Twitter 1374363950926737409
GigaGen@gigageninc·
9 Mar

Today Grifols announced its acquisition of GigaGen, which will support our novel method to generate a wide range of antibodies. GigaGen is currently developing the first recombinant polyclonal immunoglobulins & a portfolio of IO therapies. Read more: https://bit.ly/3quzRcZ

Reply on Twitter 1369381642985431045Retweet on Twitter 13693816429854310457Like on Twitter 13693816429854310459Twitter 1369381642985431045
GigaGen@gigageninc·
8 Mar

Today is #InternationalWomensDay2021! Thank you to our wonderful team of women at GigaGen for all of the contributions you’ve made both at our company and as #WomeninSTEM.

Reply on Twitter 1368924946097922054Retweet on Twitter 13689249460979220543Like on Twitter 13689249460979220543Twitter 1368924946097922054
© Copyright 2020 GigaGen. All Rights Reserved.
  • Twitter
  • LinkedIn
Scroll to top